Actively Recruiting
Safety and Dose-finding Study of VNX-101 Gene Therapy for Relapsed or Refractory CD19-Positive Blood Cancers
Led by Vironexis Biotherapeutics Inc. · Updated on 2026-10-26
32
Participants Needed
11
Research Sites
221 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating VNX-101, an investigational gene therapy, in patients with relapsed or refractory CD19-positive blood cancers. This Phase 12 open-label study aims to assess the safety and pharmacokinetics of VNX-101, which is designed to help T-cells target and kill malignant B-cells. The study is important as VNX-101 offers potential advantages over existing therapies, including being off-the-shelf and not requiring chemotherapy to prepare the body. The trial has two parts Part 1 focuses on finding the right dose of VNX-101 by studying about 12 adult patients to identify the minimal dose that achieves steady blood levels without causing significant toxicities. Part 2 will include about 20 patients aged 13 and older to further evaluate safety and how the therapy behaves in the body at the recommended dose. Participants receive a single intravenous infusion of VNX-101, with some possibly receiving standard chemotherapy beforehand to meet dosing requirements. Participants will be followed for up to 5 years after receiving VNX-101 to monitor safety, with long-term safety follow-up continuing for 6 to 15 years. Researchers will collect data on treatment-related adverse events, changes in B-cell counts, immune system markers, and antitumor activity. This extended monitoring helps understand the therapys effects over time and supports comprehensive safety evaluation throughout the study period.
CONDITIONS
Brief Title
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Research Team
A
Allen Reha
R
Recruitment Partner: PatientWing
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here